A detailed history of Israel Englander (Millennium Management LLC) transactions in Kura Oncology, Inc. stock. As of the latest transaction made, Millennium Management LLC holds 845,194 shares of KURA stock, worth $9.13 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
845,194
Previous 339,482 148.97%
Holding current value
$9.13 Million
Previous $6.99 Million 136.3%
% of portfolio
0.01%
Previous 0.0%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$18.57 - $23.23 $9.39 Million - $11.7 Million
505,712 Added 148.97%
845,194 $16.5 Million
Q2 2024

Aug 14, 2024

SELL
$17.53 - $22.98 $2.61 Million - $3.42 Million
-148,734 Reduced 30.46%
339,482 $6.99 Million
Q1 2024

May 15, 2024

BUY
$13.42 - $23.53 $4.77 Million - $8.37 Million
355,726 Added 268.49%
488,216 $10.4 Million
Q4 2023

Feb 14, 2024

SELL
$7.58 - $14.38 $2 Million - $3.79 Million
-263,681 Reduced 66.56%
132,490 $1.91 Million
Q2 2023

Aug 14, 2023

BUY
$9.62 - $13.99 $3.61 Million - $5.25 Million
374,981 Added 1769.61%
396,171 $4.19 Million
Q1 2023

May 15, 2023

SELL
$10.71 - $14.6 $381,661 - $520,285
-35,636 Reduced 62.71%
21,190 $259,000
Q4 2022

Feb 14, 2023

SELL
$11.23 - $16.9 $4.58 Million - $6.89 Million
-407,629 Reduced 87.77%
56,826 $705,000
Q3 2022

Nov 14, 2022

BUY
$12.01 - $19.45 $4.82 Million - $7.81 Million
401,725 Added 640.4%
464,455 $6.34 Million
Q2 2022

Aug 15, 2022

SELL
$10.71 - $18.33 $998,889 - $1.71 Million
-93,267 Reduced 59.79%
62,730 $1.15 Million
Q1 2022

May 16, 2022

SELL
$11.78 - $16.98 $1.13 Million - $1.63 Million
-95,765 Reduced 38.04%
155,997 $2.51 Million
Q4 2021

Feb 14, 2022

BUY
$12.22 - $19.57 $1.85 Million - $2.96 Million
151,149 Added 150.23%
251,762 $3.53 Million
Q3 2021

Nov 15, 2021

SELL
$15.42 - $21.72 $4.49 Million - $6.32 Million
-291,202 Reduced 74.32%
100,613 $1.88 Million
Q2 2021

Aug 16, 2021

BUY
$20.85 - $29.88 $1.39 Million - $1.99 Million
66,711 Added 20.52%
391,815 $8.17 Million
Q1 2021

May 17, 2021

BUY
$24.75 - $39.14 $2.9 Million - $4.59 Million
117,192 Added 56.37%
325,104 $9.19 Million
Q4 2020

Feb 16, 2021

BUY
$29.0 - $41.62 $6.03 Million - $8.65 Million
207,912 New
207,912 $6.79 Million
Q3 2020

Nov 16, 2020

SELL
$16.3 - $30.64 $2.69 Million - $5.05 Million
-164,857 Closed
0 $0
Q2 2020

Aug 14, 2020

SELL
$7.95 - $18.81 $2.51 Million - $5.94 Million
-315,861 Reduced 65.71%
164,857 $2.69 Million
Q1 2020

May 14, 2020

SELL
$6.45 - $14.04 $961,108 - $2.09 Million
-149,009 Reduced 23.66%
480,718 $4.78 Million
Q4 2019

Feb 14, 2020

BUY
$12.97 - $15.94 $8.17 Million - $10 Million
629,727 New
629,727 $8.66 Million
Q3 2019

Nov 14, 2019

SELL
$14.75 - $20.87 $1.43 Million - $2.02 Million
-96,943 Closed
0 $0
Q2 2019

Aug 14, 2019

BUY
$14.71 - $19.79 $1.24 Million - $1.67 Million
84,421 Added 674.18%
96,943 $1.91 Million
Q1 2019

May 14, 2019

SELL
$13.73 - $16.87 $169,290 - $208,007
-12,330 Reduced 49.61%
12,522 $208,000
Q4 2018

Feb 14, 2019

SELL
$10.6 - $17.49 $4.42 Million - $7.29 Million
-417,095 Reduced 94.38%
24,852 $349,000
Q3 2018

Nov 14, 2018

SELL
$16.65 - $21.85 $1.38 Million - $1.81 Million
-82,925 Reduced 15.8%
441,947 $7.73 Million
Q2 2018

Aug 14, 2018

BUY
$14.8 - $18.8 $39,382 - $50,026
2,661 Added 0.51%
524,872 $9.55 Million
Q1 2018

May 15, 2018

BUY
$14.5 - $23.4 $3.17 Million - $5.11 Million
218,306 Added 71.83%
522,211 $9.79 Million
Q4 2017

Feb 14, 2018

BUY
$13.5 - $16.65 $1.08 Million - $1.33 Million
79,989 Added 35.72%
303,905 $4.65 Million
Q3 2017

Nov 14, 2017

BUY
$6.05 - $14.95 $1.35 Million - $3.35 Million
223,916
223,916 $3.35 Million

Others Institutions Holding KURA

About Kura Oncology, Inc.


  • Ticker KURA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 66,893,000
  • Market Cap $722M
  • Description
  • Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A p...
More about KURA
Track Israel Englander's Portfolio

Track Israel Englander Portfolio

Follow Israel Englander (Millennium Management LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.